Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012;3(3):202-7.
doi: 10.5847/wjem.j.issn.1920-8642.2012.03.008.

Risk factors and antibiotic resistance of pneumonia caused by multidrug resistant Acinetobacter baumannii in pediatric intensive care unit

Xiao-Fang Cai  1 , Ji-Min Sun  1 , Lian-Sheng Bao  2 , Wen-Bin Li  3
Affiliations

Risk factors and antibiotic resistance of pneumonia caused by multidrug resistant Acinetobacter baumannii in pediatric intensive care unit

Xiao-Fang Cai et al. World J Emerg Med. 2012.

Abstract

Background: With beta-lactam drugs and immunosuppressants widely used, the infection caused by Acinetobacter baumannii (Ab) has become more and more serious with multidrug resistant Acinetobacter baumannii (MDRAb) emerging and worsening rapidly. Compared with other patients, the incidence and multidrug resistance of MDRAb are higher in children in pediatric intensive care unit (PICU) because of immune deficiency, severe basic diseases, prolonged hospitalization and invasive operations. Hence it is significant to study the epidemiology and changes of antibacterial susceptibility in order to reduce the incidence of MDRAb in children.

Methods: A total 115 patients with MDRAb pneumonia and 45 patients with negative MDRAb (NMDRAb) pneumonia who had been treated from January 2009 to August 2011 were studied retrospectively at the PICU of Wuhan Children's Hospital. Clinical data were analyzed with univariate and multivariate Logistic regression.

Results: In 176 clinical strains of Acinetobacter baumannii isolated, there were 128 strains of MDRAb, accounting for 72.73%. Drug susceptibility tests showed that the resistance rates of β-lactam antibiotics were more than 70% except for cefoperazone sulbactam. The rates to carbapenems were higher than 90%. They were significantly higher than those of NMDRAb. Amikacin, levofloxacin, ciprofloxacin and minocycline had the lowest drug-resistance rates (<20%). Multivariate Logistic regression revealed that ICU stay, the time of mechanical ventilation, anemia, hypoproteinemia and the use of carbapenems were independent risk factors for MDRAb pneumonia.

Conclusions: MDRAb is an important opportunistic pathogen to pneumonia in PICU, and its drug-resistance is severe. It increases significantly the mortality of patients. It is important to take the effective prevention measures for controlling it.

Keywords: Acinetobacter baumannii; Intensive Care Unit; Multidrug resistance; Pediatric; Pneumonia; Retrospective study; Risk factor.

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest: No benefits in any form have been received or will be received from a commercial party related directly or indirectly to the subject of this article.

References

    1. Munoz-price LS, Weinstein RA. Acinetobacter infection. N Engl J Med. 2008;358:1271–1281. - PubMed
    1. Qin XP, Wang LY, Xu WJ. Acinetobacter baumannii Infection in Children and Hospital Infection Control. Chin J Nosocomiol. 2009;19:1305–1307.
    1. Chinese Society of Respiratory Diseases. Chinese consensus guidelines on the diagnosis and treatment of hospital acquired pneumonia (draft) Chin J Tuberc Respir Dis. 1999;22:201–204.
    1. CLSI; 2008. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. Eighteenth informational supplement; pp. M100–S18.
    1. Chiang DH, Wang CC, Kuo HY, Chen HP, Chen TL, Wang FD, et al. Risk factors for mortality in patients with Acinetobacter baumannii bloodstream infection with genotypic species identification. J Microbiol Immunol Infect. 2008;41:397–402. - PubMed

LinkOut - more resources